We report the efficacy of the addition of pioglitazone (15∼30 mg/day) in 4 type 2 diabetic patients (1 female, 3 male), in whom the glycemic control conferred by glibenclamide had loaned with time. All the patients had been initiated on treatment with glibenclamide (0.625 mg), followed by satisfactory decrease of the HbA
1c value. However, continued diminish admnistration of glibenclamide was associated with waning treatment efficacy. Therefore, in 3 cases, the dose of glibenclamide was increased together with the addition of 100 mg of buformin. While 2 of the 3 cases initially showed a good response to the addition of buformin, the HbA
1c again began to increase gradually. As the HbA
1c levels of over 8% persisted, we regarded glibenclamide as affording poor glycemic control. In the remaining 1 case, the HbA
1c increased to more than 8%, therefore, additional therapy with intermediate-acting insulin was initiated.
Pioglitazone was then given the all cases, with remarkable decrease of the HbA
1c in all, and the dose of glibenclamide was reduced to less than 1.25 mg. Satisfactory glycemic control was maintained for another 2∼3 years, suggesting the dissolutionizing effect of pioglitazone on the longitudinal deterioration of glycemic control with glibenclamide therapy.
View full abstract